Neutrophilic dermatosis complicating lenalidomide therapy - 07/08/11
Doi : 10.1016/j.jaad.2008.12.011
Khanh P. Thieu, BS a, Misha Rosenbach, MD b, Xiaowei Xu, MD, PhD c, Joseph M. Kist, MD b, ⁎
a Harvard Medical School, Boston, Massachusetts
b Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
c Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Reprint requests: Joseph M. Kist, MD, Department of Dermatology, Hospital of University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104.Abstract |
Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent introduced in 2004 for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of myelodysplastic syndrome and is currently under investigative use for metastatic melanoma. We present a case of neutrophilic dermatosis involving predominantly the lower extremities in a patient receiving lenalidomide therapy for multiple myeloma.
Le texte complet de cet article est disponible en PDF.Key words : lenalidomide, neutrophilic dermatosis
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
© 2009
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 61 - N° 4
P. 709-710 - octobre 2009 Retour au numéro
Article précédent
- Alopecia secondary to mesotherapy
- Bruna Duque-Estrada, Colombina Vincenzi, Cosimo Misciali, Antonella Tosti
- Palisaded neutrophilic granulomatous dermatitis associated with systemic lupus erythematosus presenting with the burning rope sign
- Abha Gulati, David Paige, Magdi Yaqoob, Charlotte M. Proby, Rino Cerio, Catherine A. Harwood
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?